CHIP在乳腺癌组织中的表达及其临床意义

目的 探讨Hsc70羧基末端反应蛋白（CHIP）在乳腺癌组织中的表达及其与临床病理特征、分子分型的关系。方法 采用免疫组化检测128例乳腺癌组织中CHIP蛋白的表达，分析CHIP表达与临床病理特征以及与不同分子分型乳腺癌的关系。结果 乳腺癌组织中CHIP阳性表达率为60.2%，Ⅲ、Ⅳ期乳腺癌患者CHIP阳性表达率为43.2%，显著低于Ⅰ、Ⅱ期的67.0%；伴有淋巴结转移者CHIP阳性表达率显著低于无淋巴结转移者，差异有统计学意义（P＜0.05）； Luminal A型、Luminal B型、HER-2型、Basal-like型中CHIP阳性表达率分别为66.7%、70.5%、50.0%和44.0%，差异亦具有统计学意义（P＜0.05）。CHIP表达与年龄、组织学分级、肿瘤大小、有无远处转移及HER-2表达等无关。结论 乳腺癌CHIP表达与肿瘤发生发展密切相关，并可能作为预测患者复发风险的指标。

The expression of CHIP in human breast cancer and its clinical significance

Objective To investigate the expression of carboxyl teminus of Hsc70-interacting protein （CHIP） in human breast cancer and its clinical significance. Methods Expression of CHIP was detected by the immunohistochemistry in 128 cases of breast cancer specimens. The CHIP expression in breast cancer and its relationship with clinicopathological features and molecular types were analyzed using non-parametric statistical test method. Results The positive rate of CHIP in breast cancer was 60.2%； and the positive rate in clinical stage Ⅲ-Ⅳ was 43.2%， which was significantly lower than 67.0% in stageⅠ-Ⅱ（P＜0.05）. CHIP positive expression rate in cases with lymph node metastasis was lower than that of patients without lymph node metastasis （P＜0.05）. CHIP positive expression rates of Luminal A subtype， Luminal B subtype， HER-2 subtype and Basal-like subtype patients were 66.7%， 70.5%， 50.0% and 44.0%，repectively （P＜0.05）. The level of expression of CHIP has no significant difference with age， histological grade， tumor size, distant metastasis or HER-2 status. Conclusion The expression of CHIP may relate to tumorgenesis and development， and it might be used as a predictor of recurrent risk.